Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.
Reinhard Dummer(University Hospital of Zurich), Axel Hauschild(University Hospital Schleswig-Holstein), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Lisa Licitra(University of Milan), Thomas Jouary(Hôpital Saint-André), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nicole Basset‐Séguin(Université Paris Cité), Kate Fife(Addenbrooke's Hospital), Jean‐Jacques Grob(Aix-Marseille Université), B. Guillot(Université de Montpellier), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), D. Scott Ernst, Laurent Mortier, Rainer Kunstfeld(Vienna General Hospital), Sarah Williams(Ruhrlandklinik), Johan Hansson(Karolinska Institutet), Brigitte Dréno(Nantes Université), Ioannis Xynos(AstraZeneca (United Kingdom)), A. Fittipaldo(Roche (United Kingdom))
Cited by 22
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k